Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)

Trial Profile

Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Mitoxantrone (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 19 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top